Does the media refer more to BBIO or LEGN?

In the previous week, BridgeBio Pharma had 5 more articles in the media than Legend Biotech. MarketBeat recorded 13 mentions for BridgeBio Pharma and 8 mentions for Legend Biotech. BridgeBio Pharma's average media sentiment score of 0.90 beat Legend Biotech's score of 0.74 indicating that BridgeBio Pharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BridgeBio Pharma 6 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Legend Biotech 2 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher valuation & earnings, EXEL or LEGN?

Exelixis has higher revenue and earnings than Legend Biotech. Legend Biotech is trading at a lower price-to-earnings ratio than Exelixis, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Exelixis $2.44B 5.71 $782.57M $3.18 17.65 Legend Biotech $1.27B 2.84 -$296.80M -$0.25 N/A

Is EXEL or LEGN more profitable?

Exelixis has a net margin of 35.33% compared to Legend Biotech's net margin of -7.21%. Exelixis' return on equity of 42.17% beat Legend Biotech's return on equity. Company Net Margins Return on Equity Return on Assets Exelixis 35.33% 42.17% 31.76% Legend Biotech -7.21% -8.71% -5.40%

Does the media favor EXEL or LEGN?

In the previous week, Exelixis had 19 more articles in the media than Legend Biotech. MarketBeat recorded 27 mentions for Exelixis and 8 mentions for Legend Biotech. Legend Biotech's average media sentiment score of 0.74 beat Exelixis' score of 0.54 indicating that Legend Biotech is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Exelixis 12 Very Positive mention(s) 3 Positive mention(s) 3 Neutral mention(s) 2 Negative mention(s) 6 Very Negative mention(s) Positive Legend Biotech 2 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor SMMT or LEGN?

In the previous week, Summit Therapeutics had 1 more articles in the media than Legend Biotech. MarketBeat recorded 9 mentions for Summit Therapeutics and 8 mentions for Legend Biotech. Summit Therapeutics' average media sentiment score of 1.19 beat Legend Biotech's score of 0.74 indicating that Summit Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Summit Therapeutics 6 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Legend Biotech 2 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor BMRN or LEGN?

In the previous week, BioMarin Pharmaceutical had 13 more articles in the media than Legend Biotech. MarketBeat recorded 21 mentions for BioMarin Pharmaceutical and 8 mentions for Legend Biotech. BioMarin Pharmaceutical's average media sentiment score of 0.79 beat Legend Biotech's score of 0.74 indicating that BioMarin Pharmaceutical is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BioMarin Pharmaceutical 8 Very Positive mention(s) 4 Positive mention(s) 6 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Legend Biotech 2 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer LEGN or HALO?

In the previous week, Halozyme Therapeutics had 5 more articles in the media than Legend Biotech. MarketBeat recorded 13 mentions for Halozyme Therapeutics and 8 mentions for Legend Biotech. Halozyme Therapeutics' average media sentiment score of 1.02 beat Legend Biotech's score of 0.74 indicating that Halozyme Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Legend Biotech 2 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Halozyme Therapeutics 9 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Legend Biotech (LEGN) Competitors

$18.64 -0.55 (-2.87%)

Closing price 09/11/2026 04:00 PM Eastern

Extended Trading

$18.99 +0.35 (+1.86%)

As of 09/11/2026 07:39 PM Eastern

Compare

LEGN vs. BBIO, EXEL, SMMT, BMRN, and HALO

Should you buy Legend Biotech stock or one of its competitors? Legend Biotech's main competitors and comparable companies include BridgeBio Pharma (BBIO), Exelixis (EXEL), Summit Therapeutics (SMMT), BioMarin Pharmaceutical (BMRN), and Halozyme Therapeutics (HALO). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Legend Biotech compare to BridgeBio Pharma?

BridgeBio Pharma (NASDAQ:BBIO) and Legend Biotech (NASDAQ:LEGN) are both healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, analyst recommendations, institutional ownership, risk, media sentiment, profitability, earnings and valuation.

BridgeBio Pharma has a beta of 0.97, meaning that its share price is 3% less volatile than the broader market. Comparatively, Legend Biotech has a beta of 0.4, meaning that its share price is 60% less volatile than the broader market.

In the previous week, BridgeBio Pharma had 5 more articles in the media than Legend Biotech. MarketBeat recorded 13 mentions for BridgeBio Pharma and 8 mentions for Legend Biotech. BridgeBio Pharma's average media sentiment score of 0.90 beat Legend Biotech's score of 0.74 indicating that BridgeBio Pharma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BridgeBio Pharma	6 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Legend Biotech	2 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

99.8% of BridgeBio Pharma shares are owned by institutional investors. Comparatively, 70.9% of Legend Biotech shares are owned by institutional investors. 14.2% of BridgeBio Pharma shares are owned by company insiders. Comparatively, 0.0% of Legend Biotech shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Legend Biotech has higher revenue and earnings than BridgeBio Pharma. Legend Biotech is trading at a lower price-to-earnings ratio than BridgeBio Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BridgeBio Pharma	$713.07M	19.86	-$724.93M	-$3.57	N/A
Legend Biotech	$1.27B	2.84	-$296.80M	-$0.25	N/A

Legend Biotech has a net margin of -7.21% compared to BridgeBio Pharma's net margin of -97.03%. BridgeBio Pharma's return on equity of 0.00% beat Legend Biotech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BridgeBio Pharma	-97.03%	N/A	-61.19%
Legend Biotech	-7.21%	-8.71%	-5.40%

BridgeBio Pharma currently has a consensus price target of $102.61, indicating a potential upside of 41.65%. Legend Biotech has a consensus price target of $53.14, indicating a potential upside of 185.10%. Given Legend Biotech's higher possible upside, analysts clearly believe Legend Biotech is more favorable than BridgeBio Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BridgeBio Pharma	1 Sell rating(s)	2 Hold rating(s)	20 Buy rating(s)	0 Strong Buy rating(s)	2.83
Legend Biotech	1 Sell rating(s)	6 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.47

Summary

BridgeBio Pharma beats Legend Biotech on 10 of the 16 factors compared between the two stocks.

How does Legend Biotech compare to Exelixis?

Exelixis (NASDAQ:EXEL) and Legend Biotech (NASDAQ:LEGN) are both healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their valuation, risk, analyst recommendations, earnings, dividends, institutional ownership, media sentiment and profitability.

Exelixis has a net margin of 35.33% compared to Legend Biotech's net margin of -7.21%. Exelixis' return on equity of 42.17% beat Legend Biotech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Exelixis	35.33%	42.17%	31.76%
Legend Biotech	-7.21%	-8.71%	-5.40%

Exelixis has higher revenue and earnings than Legend Biotech. Legend Biotech is trading at a lower price-to-earnings ratio than Exelixis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Exelixis	$2.44B	5.71	$782.57M	$3.18	17.65
Legend Biotech	$1.27B	2.84	-$296.80M	-$0.25	N/A

85.3% of Exelixis shares are held by institutional investors. Comparatively, 70.9% of Legend Biotech shares are held by institutional investors. 2.6% of Exelixis shares are held by insiders. Comparatively, 0.0% of Legend Biotech shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Exelixis has a beta of 0.42, indicating that its stock price is 58% less volatile than the broader market. Comparatively, Legend Biotech has a beta of 0.4, indicating that its stock price is 60% less volatile than the broader market.

In the previous week, Exelixis had 19 more articles in the media than Legend Biotech. MarketBeat recorded 27 mentions for Exelixis and 8 mentions for Legend Biotech. Legend Biotech's average media sentiment score of 0.74 beat Exelixis' score of 0.54 indicating that Legend Biotech is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Exelixis	12 Very Positive mention(s)	3 Positive mention(s)	3 Neutral mention(s)	2 Negative mention(s)	6 Very Negative mention(s)	Positive
Legend Biotech	2 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Exelixis presently has a consensus price target of $50.07, suggesting a potential downside of 10.79%. Legend Biotech has a consensus price target of $53.14, suggesting a potential upside of 185.10%. Given Legend Biotech's stronger consensus rating and higher possible upside, analysts plainly believe Legend Biotech is more favorable than Exelixis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Exelixis	1 Sell rating(s)	12 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.38
Legend Biotech	1 Sell rating(s)	6 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.47

Summary

Exelixis beats Legend Biotech on 13 of the 17 factors compared between the two stocks.

How does Legend Biotech compare to Summit Therapeutics?

Summit Therapeutics (NASDAQ:SMMT) and Legend Biotech (NASDAQ:LEGN) are both healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, risk, valuation, media sentiment, analyst recommendations, earnings, institutional ownership and profitability.

Legend Biotech has higher revenue and earnings than Summit Therapeutics. Legend Biotech is trading at a lower price-to-earnings ratio than Summit Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Summit Therapeutics	N/A	N/A	-$1.08B	-$1.12	N/A
Legend Biotech	$1.27B	2.84	-$296.80M	-$0.25	N/A

Summit Therapeutics currently has a consensus target price of $25.91, indicating a potential upside of 47.63%. Legend Biotech has a consensus target price of $53.14, indicating a potential upside of 185.10%. Given Legend Biotech's higher probable upside, analysts plainly believe Legend Biotech is more favorable than Summit Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Summit Therapeutics	1 Sell rating(s)	8 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.47
Legend Biotech	1 Sell rating(s)	6 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.47

4.6% of Summit Therapeutics shares are held by institutional investors. Comparatively, 70.9% of Legend Biotech shares are held by institutional investors. 83.5% of Summit Therapeutics shares are held by company insiders. Comparatively, 0.0% of Legend Biotech shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

In the previous week, Summit Therapeutics had 1 more articles in the media than Legend Biotech. MarketBeat recorded 9 mentions for Summit Therapeutics and 8 mentions for Legend Biotech. Summit Therapeutics' average media sentiment score of 1.19 beat Legend Biotech's score of 0.74 indicating that Summit Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Summit Therapeutics	6 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Legend Biotech	2 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summit Therapeutics has a beta of -1.24, indicating that its share price is 224% less volatile than the broader market. Comparatively, Legend Biotech has a beta of 0.4, indicating that its share price is 60% less volatile than the broader market.

Summit Therapeutics has a net margin of 0.00% compared to Legend Biotech's net margin of -7.21%. Legend Biotech's return on equity of -8.71% beat Summit Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Summit Therapeutics	N/A	-168.94%	-141.92%
Legend Biotech	-7.21%	-8.71%	-5.40%

Summary

Legend Biotech beats Summit Therapeutics on 9 of the 16 factors compared between the two stocks.

How does Legend Biotech compare to BioMarin Pharmaceutical?

BioMarin Pharmaceutical (NASDAQ:BMRN) and Legend Biotech (NASDAQ:LEGN) are both healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, analyst recommendations, earnings, valuation, institutional ownership, dividends, media sentiment and profitability.

BioMarin Pharmaceutical presently has a consensus price target of $89.17, indicating a potential upside of 35.77%. Legend Biotech has a consensus price target of $53.14, indicating a potential upside of 185.10%. Given Legend Biotech's higher possible upside, analysts clearly believe Legend Biotech is more favorable than BioMarin Pharmaceutical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioMarin Pharmaceutical	1 Sell rating(s)	6 Hold rating(s)	14 Buy rating(s)	2 Strong Buy rating(s)	2.74
Legend Biotech	1 Sell rating(s)	6 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.47

BioMarin Pharmaceutical has a net margin of 2.14% compared to Legend Biotech's net margin of -7.21%. BioMarin Pharmaceutical's return on equity of 5.32% beat Legend Biotech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BioMarin Pharmaceutical	2.14%	5.32%	3.69%
Legend Biotech	-7.21%	-8.71%	-5.40%

BioMarin Pharmaceutical has higher revenue and earnings than Legend Biotech. Legend Biotech is trading at a lower price-to-earnings ratio than BioMarin Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioMarin Pharmaceutical	$3.22B	3.95	$348.90M	$0.37	177.51
Legend Biotech	$1.27B	2.84	-$296.80M	-$0.25	N/A

BioMarin Pharmaceutical has a beta of 0.24, indicating that its share price is 76% less volatile than the broader market. Comparatively, Legend Biotech has a beta of 0.4, indicating that its share price is 60% less volatile than the broader market.

In the previous week, BioMarin Pharmaceutical had 13 more articles in the media than Legend Biotech. MarketBeat recorded 21 mentions for BioMarin Pharmaceutical and 8 mentions for Legend Biotech. BioMarin Pharmaceutical's average media sentiment score of 0.79 beat Legend Biotech's score of 0.74 indicating that BioMarin Pharmaceutical is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BioMarin Pharmaceutical	8 Very Positive mention(s)	4 Positive mention(s)	6 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Legend Biotech	2 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

98.7% of BioMarin Pharmaceutical shares are held by institutional investors. Comparatively, 70.9% of Legend Biotech shares are held by institutional investors. 0.7% of BioMarin Pharmaceutical shares are held by insiders. Comparatively, 0.0% of Legend Biotech shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

BioMarin Pharmaceutical beats Legend Biotech on 15 of the 17 factors compared between the two stocks.

How does Legend Biotech compare to Halozyme Therapeutics?

Legend Biotech (NASDAQ:LEGN) and Halozyme Therapeutics (NASDAQ:HALO) are both healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, dividends, valuation, risk, earnings, profitability, media sentiment and institutional ownership.

In the previous week, Halozyme Therapeutics had 5 more articles in the media than Legend Biotech. MarketBeat recorded 13 mentions for Halozyme Therapeutics and 8 mentions for Legend Biotech. Halozyme Therapeutics' average media sentiment score of 1.02 beat Legend Biotech's score of 0.74 indicating that Halozyme Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Legend Biotech	2 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Halozyme Therapeutics	9 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

70.9% of Legend Biotech shares are owned by institutional investors. Comparatively, 97.8% of Halozyme Therapeutics shares are owned by institutional investors. 0.0% of Legend Biotech shares are owned by company insiders. Comparatively, 2.5% of Halozyme Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Halozyme Therapeutics has higher revenue and earnings than Legend Biotech. Legend Biotech is trading at a lower price-to-earnings ratio than Halozyme Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Legend Biotech	$1.27B	2.84	-$296.80M	-$0.25	N/A
Halozyme Therapeutics	$1.40B	8.71	$316.89M	$3.35	32.00

Halozyme Therapeutics has a net margin of 24.86% compared to Legend Biotech's net margin of -7.21%. Halozyme Therapeutics' return on equity of 260.98% beat Legend Biotech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Legend Biotech	-7.21%	-8.71%	-5.40%
Halozyme Therapeutics	24.86%	260.98%	23.91%

Legend Biotech has a beta of 0.4, meaning that its share price is 60% less volatile than the broader market. Comparatively, Halozyme Therapeutics has a beta of 0.88, meaning that its share price is 12% less volatile than the broader market.

Legend Biotech presently has a consensus target price of $53.14, suggesting a potential upside of 185.10%. Halozyme Therapeutics has a consensus target price of $91.20, suggesting a potential downside of 14.93%. Given Legend Biotech's higher possible upside, equities analysts clearly believe Legend Biotech is more favorable than Halozyme Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Legend Biotech	1 Sell rating(s)	6 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.47
Halozyme Therapeutics	1 Sell rating(s)	3 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.62

Summary

Halozyme Therapeutics beats Legend Biotech on 15 of the 16 factors compared between the two stocks.

Get Legend Biotech News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding LEGN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

LEGN vs. The Competition

Export

Metric	Legend Biotech	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$3.72B	$3.84B	$7.13B	$12.72B
Dividend Yield	N/A	3.63%	2.56%	11.15%
P/E Ratio	-74.56	14.25	275.24	25.29
Price / Sales	2.84	1,473.06	655.99	98.94
Price / Cash	N/A	106.68	77.04	51.44
Price / Book	3.43	15.12	10.33	6.20
Net Income	-$296.80M	-$22.86M	$3.50B	$358.50M
7 Day Performance	-13.38%	-4.34%	-3.32%	-2.35%
1 Month Performance	-9.73%	-0.02%	-0.41%	-2.77%
1 Year Performance	-43.70%	40.64%	19.21%	7.63%

Legend Biotech Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
LEGN Legend Biotech	3.5312 of 5 stars	$18.64 -2.9%	$53.14 +185.1%	-44.9%	$3.72B	$1.27B	N/A	2,965	News Coverage Analyst Forecast High Trading Volume
BBIO BridgeBio Pharma	3.4571 of 5 stars	$74.84 flat	$101.53 +35.7%	+37.7%	$14.63B	$502.08M	N/A	400	Analyst Forecast
EXEL Exelixis	2.4691 of 5 stars	$59.01 flat	$50.07 -15.2%	+43.6%	$14.62B	$2.32B	18.56	1,077	Trending News Analyst Forecast
SMMT Summit Therapeutics	3.6754 of 5 stars	$17.60 flat	$24.07 +36.8%	-5.6%	$14.04B	N/A	N/A	110	Positive News Analyst Forecast
BMRN BioMarin Pharmaceutical	4.6227 of 5 stars	$66.53 flat	$89.17 +34.0%	+17.5%	$12.88B	$3.22B	179.81	3,221	Positive News Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:LEGN) was last updated on 9/12/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Legend Biotech (LEGN) Competitors

LEGN vs. BBIO, EXEL, SMMT, BMRN, and HALO

How does Legend Biotech compare to BridgeBio Pharma?

Summary

How does Legend Biotech compare to Exelixis?

Summary

How does Legend Biotech compare to Summit Therapeutics?

Summary

How does Legend Biotech compare to BioMarin Pharmaceutical?

Summary

How does Legend Biotech compare to Halozyme Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LEGN vs. The Competition

Legend Biotech Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Legend Biotech (LEGN) Competitors

LEGN vs. BBIO, EXEL, SMMT, BMRN, and HALO

How does Legend Biotech compare to BridgeBio Pharma?

Which has more risk and volatility, BBIO or LEGN?

Does the media refer more to BBIO or LEGN?

Do institutionals & insiders believe in BBIO or LEGN?

Which has higher earnings and valuation, BBIO or LEGN?

Is BBIO or LEGN more profitable?

Do analysts prefer BBIO or LEGN?

Summary

How does Legend Biotech compare to Exelixis?

Is EXEL or LEGN more profitable?

Which has higher valuation & earnings, EXEL or LEGN?

Do institutionals and insiders hold more shares of EXEL or LEGN?

Which has more volatility & risk, EXEL or LEGN?

Does the media favor EXEL or LEGN?

Do analysts rate EXEL or LEGN?

Summary

How does Legend Biotech compare to Summit Therapeutics?

Which has preferable earnings and valuation, SMMT or LEGN?

Do analysts rate SMMT or LEGN?

Do institutionals & insiders hold more shares of SMMT or LEGN?

Does the media favor SMMT or LEGN?

Which has more volatility and risk, SMMT or LEGN?

Is SMMT or LEGN more profitable?

Summary

How does Legend Biotech compare to BioMarin Pharmaceutical?

Do analysts recommend BMRN or LEGN?

Is BMRN or LEGN more profitable?

Which has better valuation and earnings, BMRN or LEGN?

Which has more risk & volatility, BMRN or LEGN?

Does the media favor BMRN or LEGN?

Do insiders & institutionals hold more shares of BMRN or LEGN?

Summary

How does Legend Biotech compare to Halozyme Therapeutics?

Does the media prefer LEGN or HALO?

Do insiders and institutionals hold more shares of LEGN or HALO?

Which has stronger valuation and earnings, LEGN or HALO?

Is LEGN or HALO more profitable?

Which has more risk and volatility, LEGN or HALO?

Do analysts recommend LEGN or HALO?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LEGN vs. The Competition

Legend Biotech Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools